查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1705600

2025年胜肽和寡核苷酸CDMO全球市场报告

Peptide And Oligonucleotide CDMO Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年肽和寡核苷酸 CDMO 市场规模将快速成长。到 2029 年，这一数字将成长至 37.9 亿美元，复合年增长率为 11.9%。预测期内的成长归因于个人化医疗需求的不断增长、生物技术的进步、应用范围的扩大、外包的增加以及慢性病负担的增加。预测期内的关键趋势包括个人化治疗、技术进步、品管挑战、全球扩张以及生物製药公司之间日益加强的合作。

个人化医疗的日益普及推动了胜肽和寡核苷酸 CDMO 市场的发展。个人化医疗根据个人的基因、生活方式、环境和其他特征来制定医疗保健决策和治疗。这一趋势是由基因组技术的进步、对分子层面上疾病机制的更深入洞察以及对根据患者基因特征和病历定制的更有针对性和更有效的治疗方案的需求所推动的。胜肽和寡核苷酸受託製造厂商(CDMO) 透过生产客製化的治疗胜肽和寡核苷酸来满足个别患者的需求，在个人化医疗中发挥关键作用。例如，2024年2月，FDA药品评估与研究中心（CDER）核准了16种针对罕见疾病患者的新的个人化治疗方案，较前一年有显着增加。因此，个人化医疗的采用正在增加，推动胜肽和寡核苷酸 CDMO 市场向前发展。

胜肽和寡核苷酸 CDMO 市场的主要企业正在建立策略伙伴关係，以增强其服务产品、加强技术力并扩大其市场占有率。胜肽开发和生产伙伴关係涉及组织之间的合作，以开发和製造基于胜肽的疗法。例如，2023 年 5 月，PolyPeptide Group AG 与 Numaferm GmbH 合作进行胜肽的开发和生产。此次合作利用了 Numaferm 在永续肽製造和生化生产平台方面的专业知识，以及 cGMP 製造能力和多肽市场进入。目的是合作探索开发合适的胜肽候选物，以实现基于胜肽的原料药的更永续生产。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球胜肽和寡核苷酸 CDMO PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球胜肽和寡核苷酸 CDMO 市场：增长率分析
  • 全球胜肽和寡核苷酸 CDMO 市场表现：规模与成长，2019-2024 年
  • 全球胜肽与寡核苷酸 CDMO 市场预测：规模与成长，2024-2029 年，2034 年
  • 全球胜肽和寡核苷酸 CDMO 总目标市场（TAM）

第六章市场区隔

  • 全球胜肽和寡核苷酸 CDMO 市场（按产品、绩效和预测）：2019-2024 年、2024-2029 年、2034 年
  • 胜肽
  • 寡核苷酸
  • 全球胜肽和寡核苷酸 CDMO 市场（按服务类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 合约开发
  • 契约製造
  • 全球胜肽和寡核苷酸 CDMO 市场的应用、性能和预测（2019-2024 年、2024-2029 年预测、2034 年预测）
  • 治疗
  • 调查应用
  • 诊断
  • 其他用途
  • 全球胜肽和寡核苷酸 CDMO 市场（按最终用户、绩效和预测）2019-2024 年、2024-2029 年、2034 年
  • 生物製药公司
  • 製药公司
  • 研究组织
  • 学术和政府机构
  • 其他最终用户
  • 全球胜肽和寡核苷酸 CDMO 市场细分（按肽类型、实际和预测），2019-2024 年、2024-2029 年、2034 年
  • 活性药物成分（Apis）
  • 胜肽类药物
  • 胜肽合成和製造服务
  • 全球胜肽和寡核苷酸 CDMO 市场细分（按寡核苷酸类型、实际及预测），2019-2024 年、2024-2029 年、2034 年
  • 反义寡核苷酸
  • sirna和mrna寡核苷酸
  • 寡核苷酸合成与製造服务

第七章 区域和国家分析

  • 全球胜肽与寡核苷酸 CDMO 市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球胜肽和寡核苷酸 CDMO 市场：按国家/地区、绩效和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 胜肽和寡核苷酸 CDMO 市场：竞争格局
  • 胜肽和寡核苷酸 CDMO 市场：公司简介
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Catalent Inc.
  • Piramal Pharma Ltd
  • Curia Global Inc.
  • Almac Group
  • Euroapi SA.
  • CordenPharma International
  • Bachem Holding AG
  • Genscript Biotech Corporation
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Ambiopharm Inc
  • ScinoPharm
  • Senn Chemicals AG
  • Aurigene Pharmaceutical Services
  • Creative Peptides

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029 年胜肽和寡核苷酸 CDMO 市场：提供新机会的国家
  • 2029 年胜肽和寡核苷酸 CDMO 市场：细分领域带来新机会
  • 2029 年胜肽和寡核苷酸 CDMO 市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r30918

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that offers services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations specialize in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.

The main product types provided by peptide and oligonucleotide CDMOs are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. These CDMOs offer services including contract development and contract manufacturing. Peptides and oligonucleotides find applications in therapeutics, research applications, diagnostics, and other fields, and are utilized by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, among others.

The peptide and oligonucleotide CDMO market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide CDMO market statistics, including the peptide and oligonucleotide CDMO industry global market size, regional shares, competitors with peptide and oligonucleotide CDMO market share, detailed peptide and oligonucleotide CDMO market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide CDMO industry. These peptide and oligonucleotide CDMO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.16 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.

The peptide and oligonucleotide CDMO markets are poised for growth, driven by the increasing adoption of personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual characteristics such as genetics, lifestyle, and environment. This trend is fueled by advancements in genomic technologies, deeper insights into disease mechanisms at the molecular level, and the demand for more targeted and effective treatment options customized to patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a pivotal role in personalized medicine by producing customized therapeutic peptides and oligonucleotides to meet individual patient needs. For example, in February 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a notable increase from the previous year. Consequently, the rising adoption of personalized medicine is propelling the peptide and oligonucleotide CDMO market forward.

Key players in the peptide and oligonucleotide CDMO market are forging strategic partnerships to enrich their service offerings, enhance technological capabilities, and broaden market presence. Peptide development and production partnerships entail collaborative efforts between organizations to develop and manufacture peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG teamed up with Numaferm GmbH for peptide development and production. This collaboration harnesses PolyPeptide's cGMP manufacturing capacities and market access alongside Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The aim is to jointly explore the development of suitable peptide candidates for more sustainable production of peptide-based APIs.

In May 2024, EUROAPI strengthened its foothold in the oligonucleotide CDMO market by acquiring BianoGMP, further enhancing its capacity in Frankfurt. BianoGMP, a Germany-based CDMO specializing in providing analytical services for oligonucleotides, augments EUROAPI's capabilities, positioning it for expanded growth and innovation in the oligonucleotide segment.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Others End Users
  • Subsegments:
  • 1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
  • 2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide And Oligonucleotide CDMO Market Characteristics

3. Peptide And Oligonucleotide CDMO Market Trends And Strategies

4. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Peptide And Oligonucleotide CDMO Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Peptide And Oligonucleotide CDMO Market Growth Rate Analysis
  • 5.4. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM)

6. Peptide And Oligonucleotide CDMO Market Segmentation

  • 6.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Peptides
  • Oligonucleotides
  • 6.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Contract Development
  • Contract Manufacturing
  • 6.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutics
  • Research Applications
  • Diagnostics
  • Other Applications
  • 6.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others End Users
  • 6.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Active Pharmaceutical Ingredients (Apis)
  • Peptide Drug Products
  • Peptide Synthesis And Manufacturing Services
  • 6.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotides
  • Sirna And Mrna Oligonucleotides
  • Oligonucleotide Synthesis And Manufacturing Services

7. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 8.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide And Oligonucleotide CDMO Market

  • 9.1. China Peptide And Oligonucleotide CDMO Market Overview
  • 9.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide And Oligonucleotide CDMO Market

  • 10.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide And Oligonucleotide CDMO Market

  • 11.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • 11.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide And Oligonucleotide CDMO Market

  • 12.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide And Oligonucleotide CDMO Market

  • 13.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide And Oligonucleotide CDMO Market

  • 14.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • 14.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide And Oligonucleotide CDMO Market

  • 15.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • 15.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide And Oligonucleotide CDMO Market

  • 16.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide And Oligonucleotide CDMO Market

  • 17.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide And Oligonucleotide CDMO Market

  • 18.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide And Oligonucleotide CDMO Market

  • 19.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide And Oligonucleotide CDMO Market

  • 20.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 21.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • 21.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide And Oligonucleotide CDMO Market

  • 22.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide And Oligonucleotide CDMO Market

  • 23.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • 23.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide And Oligonucleotide CDMO Market

  • 24.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • 24.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide And Oligonucleotide CDMO Market

  • 25.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • 25.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide And Oligonucleotide CDMO Market

  • 26.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • 26.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide And Oligonucleotide CDMO Market

  • 27.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide And Oligonucleotide CDMO Market

  • 28.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • 28.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide And Oligonucleotide CDMO Market

  • 29.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • 29.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 30.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape
  • 30.2. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • 31.1. Catalent Inc.
  • 31.2. Piramal Pharma Ltd
  • 31.3. Curia Global Inc.
  • 31.4. Almac Group
  • 31.5. Euroapi SA.
  • 31.6. CordenPharma International
  • 31.7. Bachem Holding AG
  • 31.8. Genscript Biotech Corporation
  • 31.9. PolyPeptide Group
  • 31.10. Rentschler Biopharma SE
  • 31.11. Ambiopharm Inc
  • 31.12. ScinoPharm
  • 31.13. Senn Chemicals AG
  • 31.14. Aurigene Pharmaceutical Services
  • 31.15. Creative Peptides

32. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

34. Recent Developments In The Peptide And Oligonucleotide CDMO Market

35. Peptide And Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies

  • 35.1 Peptide And Oligonucleotide CDMO Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Peptide And Oligonucleotide CDMO Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Peptide And Oligonucleotide CDMO Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer